MinuteCE®
A robust collection of short-form, digestible CE activities that are made to fit into any schedule. With MinuteCE, you’re in control of the content you want, when you want it. To start microlearning, follow these simple steps:
Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
Why choose microlearning?
- Bite-sized episodes
- The most relevant content
- Improved retention
To experience MinuteCE for yourself, select one of the episodes below to start learning!
Episodes 391-405 of 455
Case Consult: Adjuvant Therapy Following Localized Treatment for Stage III Melanoma
MinuteCE®Case Consult: Adjuvant Therapy Following Localized Treatment for Stage III Melanoma
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
MinuteCE®Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Navigating Adjuvant ICI Treatment in Stage II Melanoma: A Patient Case Presentation
MinuteCE®Navigating Adjuvant ICI Treatment in Stage II Melanoma: A Patient Case Presentation
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
MinuteCE®First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
Future Directions: Targeting LAG-3 in Melanoma Treatment
MinuteCE®Future Directions: Targeting LAG-3 in Melanoma Treatment
What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage III/IV Melanoma
MinuteCE®What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage III/IV Melanoma
Optimizing Resectable Melanoma Outcomes Through Multidisciplinary Care and Multimodal Treatment Strategies
MinuteCE®Optimizing Resectable Melanoma Outcomes Through Multidisciplinary Care and Multimodal Treatment Strategies
IBD & The Evolution of Targeted Therapies – How Far Have We Come?
MinuteCE®IBD & The Evolution of Targeted Therapies – How Far Have We Come?
Examining the Lifetime Impact of a 25-Year Misdiagnosis – Part 2
MinuteCE®Examining the Lifetime Impact of a 25-Year Misdiagnosis – Part 2
Examining the Lifetime Impact of a 25-Year Misdiagnosis – Part 1
MinuteCE®Examining the Lifetime Impact of a 25-Year Misdiagnosis – Part 1
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
MinuteCE®What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
